EXTRACELLULAR NUCLEOTIDES such as ATP, ADP, adenosine, UTP, and UDP are increasingly recognized as important regulators of a variety vascular functions, including vascular tone (3), permeability (12) , inflammation (6) , and angiogenesis (7) . All these vascular responses of extracellular nucleotides are initialized by activation of purinergic receptors (PRs) on the plasma membrane (7) . PRs have been classified into two subtypes: P1 and P2 receptors, based on their pharmacological properties and molecular structures (10, 27) . Four subtypes of P1 receptors (also termed adenosine receptors), all metabotropic, have been cloned, namely A1R, A 2A R, A 2B R, and A3R (33) . The P2 receptors belong to two major families: ionotropic P2XR and metabotropic P2YR (1, 5) . At least seven P2XR and eight P2YR have been cloned to date (4) .
Angiogenesis, the formation of new capillaries from preexisting blood vessels, occurs during normal embryonic development and in various physiological and pathological conditions (8) . Several in vitro studies have shown that activation of all four subtypes of P1R by adenosine results in angiogenesis via release of angiogenic factors (18) . Moreover, injection of an adenosine A 2A receptor agonist into diabetic mice has been shown to improve impaired wound healing and increase wound-breaking strength (13) . In addition to P1R, activation of not only P2XR receptors by ATP (19) but also P2YR by ATP, ADP, or UTP (2, 14, 35) has been reported to influence established angiogenic factors such as vascular endothelial growth factor (VEGF) leading to tubulogenesis, angiogenesis and wound repair. More recently, activation of P2Y 4 R receptors was shown to play an essential role in postnatal cardiac development (20) . Together, these findings suggest that purinergic receptors activated by extracellular nucleotides may be involved in angiogenesis.
Uridine adenosine tetraphosphate (Up 4 A), endogenously released from endothelial cells and biosynthesized by VEGF receptor type 2 (VEGFR 2 ) (23), has been identified as the first dinucleotide found in living organisms that contains both purine and pyrimidine moieties (25) . This suggests that Up 4 A is capable of activating both P1R and P2R (25, 44, 45) . Indeed, early studies regarding the effect of Up 4 A on vascular tone regulation found that Up 4 A induces vasoconstriction through P2X 1 R (25, 46) and P2YR (17) but produces vasodilation through A 2A R (44, 45) , P2X 1 R, and P2Y 1 R (44) . Recent studies performed at the cellular level showed that Up 4 A induces human smooth muscle cell proliferation via activation of P2YR (16) and is a strong activator of migration in smooth muscle cell obtained from rat thoracic aorta through activation of P2Y 2 R (42).
To date, the effect of Up 4 A on the angiogenic process has not been explored. Here, we investigated the angiogenic potential of Up 4 A. Our data show that Up 4 A stimulation promotes angiogenic tubule formation in a three-dimensional (3D) matrix system in vitro, in which the neovascular growth process is more accurately mimicked by allowing interaction of human endothelial cells with pericytes. Since the biosynthesis of Up 4 A is linked to VEGFR 2 in endothelial cells (23), we also investigated the effect of Up 4 A on the expression of wellknown angiogenic factors. In addition, we evaluated which putative PRs could be involved in the endothelial angiogenic response to Up 4 A. We found in the present study that Up 4 A mainly affected pyrimidine-favored P2YR (P2Y 6 R). We subsequently tested the effect of P2Y 6 R blockade on Up 4 Amediated angiogenesis and the expression profile of PRs, as well as angiogenic factors.
MATERIALS AND METHODS
Cell culture. Human umbilical vein endothelial cells (HUVECs), human microvascular ECs (HMVECs), human aorta ECs (HAECs), and human carotid arterial endothelial cells (HCATECs) were obtained from Lonza and maintained in EGM2 Bulletkit medium (Lonza) with 100 U/ml penicillin-streptomycin (PS). Human brain vascular pericytes were obtained from ScienCell and maintained in DMEM supplemented with 10% FCS and 100 U/ml PS. All cells were used between passages 3 and 6 (9).
HUVECs-GFP, HMVECs-GFP, and pericytes-dsRED were created by transfecting passage 1 HUVECs and pericytes at 60% confluency with lentiviral vectors encoding GFP and dsRED cDNA, respectively, at a multiplicity of infection of 5 in the presence of 6 g/ml polybrene in EBM medium with 0.2% FCS. After 6 h of transduction, the cells were incubated for 72 h in fresh growth medium and were exposed to Puromycin (1-2,5 g/ml) selection for 10 days (38) . HUVECs-GFP, HMVECs-GFP, and pericytes-dsRED batches were stored by cryopreservation before use in experiments.
Collagen-based 3D coculture. Microvessel networks were established by seeding either HUVECs-GFP, HMVECs-GFP, and pericytes-dsRED at a density of 6 ϫ 10 4 HUVECs-or HMVECs-GFP and 1.2 ϫ 10 4 pericytes-dsRED in 50 l of 2.0 mg/ml type 1 collagen (BD Bioscience), supplemented with stem cell factor, stromal-derived factor-1␣, and interleukin-3 (BD-Bioscience), each added at a concentration of 400 ng/l in the collagen matrix (39) . Subsequently, the collagen was allowed to cross link for 1 h at 37°C and 5% CO2. Depending on the test conditions, Up4A (0 M-1 M-2.5 M-5 M-10 M) and the potent/irreversible P2Y6R antagonist MRS2578 (10 M) (30, 45) were added per well in EBM2 ϩ 2%FCS ϩ ascorbic acid ϩ fibroblast growth factor-2 (obtained from the EGM2 bullitkit). After 2 days of coculture, tubule formation, and after 5 days stabilization of the newly formed tubules was monitored by fluorescence microscopy. Total tubule length, mean tubule length, and the amount of junctions were quantified with Angiosys software. See Fig. 1A for a summary of methods.
Quantitative real-time PCR analysis. Quantitative (q)-PCR was conducted to determine the effect of Up 4A in the absence and presence of P2Y6R antagonist on mRNA expression levels of putative purinergic receptors and proangiogenic factors. Either HUVECs or HAECs were seeded at a density of 200,000 cells per well in a precoated (0.1% gelatin) six-well culture plate. HUVECs or HAECs were treated with Up 4A (0 M-5 M-10 M) in the absence and presence of P2Y6R antagonist MRS2578 (10 M) in EBM2 ϩ 2%FCS ϩ ascorbic acid ϩ fibroblast growth factor-2. After a 24-h incubation at 37°C and 5% CO 2, cells were washed twice with ice cold PBS and harvested for total RNA extraction (9) . RNA was isolated using RNAeasy kit (Qiagen) and was checked for quality and quantity by spectophotometer (Nanodrop; ND-1000). Isolated RNA was reverse transcribed into cDNA according to manufacturer's instruction (Iscript; Bio-Rad). q-PCR reactions were performed using iCycles iQ5 Detection System (Bio-Rad) according to manufacturer's instructions. Sequences of the primers that were designed and used for these experiments are described in Table 1 . The mRNA expression levels were analyzed and normalized using the housekeeping gene ␤-actin or GAPDH.
Western blot analysis. HCATECs were seeded at a density of 200.000 cells per well in a precoated (0.1% gelatin) six-well culture plate. HCATECs were treated with Up4A (0 M-5 M-10 M) in EBM2 ϩ 2%FCS ϩ ascorbic acid ϩ fibroblast growth factor-2. After a 48-h incubation at 37°C and 5% CO2, cells were washed twice with ice cold PBS and harvested. Protein was extracted in RIPA Buffer (Thermo Scientific) with protease inhibitors (Roche) and centrifuged for 15 min at 12,000 g at 4°C. Total protein content of the extracts was quantified by using a bicinchoninic acid protein assay kit (Pierce Biotechnology, Life Technologies). The proteins were separated on 12% SDS gel (30 g per sample) and transferred onto PVDF membranes (Merck, Millipore, Solna, Sweden). Membranes were blocked with 5% milk for 1 h at room temperature and incubated overnight at 4°C with primary antibodies against VEGFA (1:1,000), ANGTP1 (1:500), and GAPDH (1:2,500). Band densities were analyzed with Image Studio Lite Version 3.1 (LI-COR Bio-sciences), and the data obtained were normalized to GAPDH.
Statistical analysis. Statistical analysis of the 3D coculture data was performed using GraphPad Prism statistical program or Microsoft Excel (Microsoft). Statistical significance was set at minimum with P Ͻ 0.05. Data were analyzed by one-way ANOVA, followed by post hoc analysis using Bonferroni's test. Data are presented as mean Ϯ SE, unless stated otherwise. 4 A promotes vascular tubule formation. To assess the angiogenic potential of Up 4 A, we used an in vitro coculture assay. In this assay, GFP-labeled human endothelial cells and human brain-derived dsRED-labeled pericytes were cocultivated in a 3D collagen gel setting, enabling direct interaction between these two types of vascular cells. Vascular sprouting and initiation of tubule formation was observed after 1 day, with subsequent stabilization of the vascular structures till up to 5 days postseeding. Imaging and quantification of the vascular structures were conducted at 2 and 5 days postseeding (Fig. 1A) . Different concentrations of Up 4 A were added to the cocultures at day 0, and the effect was evaluated compared with non-treated samples.
RESULTS

Up
No difference in initial tubule formation was detected between Up 4 A stimulation and control conditions at day 2. In contrast, a significant increase in vascular density in response to Up 4 A was observed at day 5 in HUVEC-pericyte coculture system (Fig. 1 , B and C). Up 4 A at a concentration of 2.5 and 5 M (but not at 10 M) promoted total tubule length (by ϳ1.89-and ϳ2.23-fold), number of tubules (by ϳ1.71-and ϳ1.89-fold), as well as number of junctions (by ϳ2.24-and ϳ2.80-fold) (Fig. 1C) . Similarly, Up 4 A at a concentration of 5 M significantly promoted angiogenesis in coculture system of HMVECs at day 5 ( Fig. 1, D and E). However, an increase in tubule formation was not detected at day 5 if Up 4 A was added at day 2 (data not shown). These findings indicate that Up 4 A is functionally capable of promoting tubule formation, and Up 4 A stimulation during early sprouting in our coculture setup is required to enhance vascular growth. 4 A on expression of purinergic receptors and angiogenic factors. Vascular tone regulation and other biological effects by Up 4 A are mediated through activation of PRs (31) . Next, we evaluated the effects of 24 h of incubation with Up 4 A on the mRNA expression profile of PRs in HUVECs. Up 4 A at a concentration of 10 M significantly increased mRNA levels of P2Y 2 R, P2Y 4 R, and P2Y 6 R ( Fig.  2A) . In contrast, mRNA levels of A 2A R, A 2B R, P2X 4 R, and P2X 7 R were not affected by Up 4 A, either at a concentration of 5 or 10 M, compared with nontreated controls (Fig. 2A) . Further evaluation of Up 4 A on expression levels of angiogenic factors showed that 10 M of Up 4 A significantly increased mRNA levels of VEGFA and ANGPT1, whereas 5 or 10 M of Up 4 A failed to increase mRNA levels of VEGFR 2 , PDGF b , ANGPT2, Tie1, and Tie2 (Fig. 2B) . Western blot analysis of protein levels of VEGFA and ANGTP1 revealed that after 48 h of treatment, Up 4 A at a concentration of 10 M significantly increased protein level of VEGFA but not ANGPT1 in HCATECs (Fig. 2C) .
Effects of Up
P2Y 6 R blockade attenuated Up 4 A-mediated vascular tubule formation.
There is a lack of selective PR antagonists for many PR subtypes. Since Up 4 A mainly affected P2YR subtypes in our setting, and MRS2578 is a selective antagonist for P2Y 6 R that previously has been well-validated by other studies, we used the MRS2578 to investigate the signaling pathway in the Up 4 A-mediated angiogenic process, using the HUVECs and pericytes coculture setup. Trace amounts of DMSO was used as a solvent for the MRS2578, but did not interfere with the assay, as controls without and with DMSO did not differ in (Fig. 3B) . Furthermore, coculture experiments with GFP labeled HMVECs and dsRED-pericytes similarly showed that Up 4 A (5 M) could induce a significant proangiogenic response that was decreased by P2Y 6 R inhibition with MRS2578, thus validating our findings with HUVEC assays (Fig. 1, D (Fig. 4A) . Moreover, P2Y 6 R blockade decreased Up 4 A (10 M)-induced mRNA expression of P2Y 2 R, whereas P2Y 6 R blockade had no effect on the expression level of A 2A R, A 2B R, and P2Y 4 R (Fig.  4A) . As for the angiogenic factors, P2Y 6 R blockade had no effect on VEGFA, ANGPT1, ANGPT2, Tie1, and Tie2 in response to Up 4 A (Fig. 4B) . Furthermore, q-PCR analysis using HAECs revealed that the transcriptional response of P2Y 6 R and ANGTP1 to Up 4 A stimulation reflects the response in HUVECs (Fig. 4C) . In contrast, VEGFA expression was not responsive to Up 4 Up 4 A, endogenously produced from endothelial cells as well as released upon mechanical (shear) stress and chemical challenges (25) , is biosynthesized by activation of VEGFR 2 (23) . The plasma concentrations of Up 4 A detected in healthy subjects are in the vasoactive range (ϳ4 nM) (25) , which can be markedly elevated in diseased condition such as hypertension (ϳ33 nM in juvenile hypertensive patients) (22) . Thus Up 4 A has been shown to regulate vascular tone in various vascular beds (31, 45) and has been implicated in blood pressure regulation (22, 25) . Moreover, the effects of Up 4 A have been shown to induce human vascular smooth muscle cell proliferation (16), rat vascular smooth muscle migration (42) , and vascular calcification in rats (37) , suggesting a critical role of Up 4 A in regulation of the homeostasis of blood vessels.
We hypothesize that Up 4 A can be locally increased to a sufficient level to promote angiogenesis in tissues undergoing, e.g., a hypoxic response or vascular strain (in case of hypertension). Indeed, (local) concentration of other nucleotides such as ATP, ADP, and adenosine with angiogenic potential have been shown to be elevated during stress and injury conditions such as myocardial infarction and hypoxia (7, 18) . Based on this assumption, we tested the potential angiogenic effect of Up 4 A on human endothelial cells. We used HUVECs as the main experimental cell type together with other endothelial cell types including HMVECs, HCATECs, and HAECs to reveal a general capacity of Up 4 A to induce angiogenesis in human endothelial cells of different origins. Indeed, Up 4 A treatment stimulated vascular sprouting and initiation of tubule formation from 1 day in the coculture setup. This was followed by subsequent stabilization of the vascular structures till up to 5 days postseeding, as evidenced by an increase in vascular density in response to Up 4 A at relatively low concentrations at day 5 (0 -5 M). Interestingly, increase in tubule formation was not detected at day 5 in HMVECs if Up 4 A was added at day 2, suggesting that Up 4 A stimulation is required in early sprouting in our coculture setup to induce angiogenic increase. Up 4 A appears to have a dose optimum at 5 M, after which the beneficial effects of Up 4 A on tubule formation are diminished. These findings indicate that Up 4 A is functionally involved in A2A  5=-CCAGACGTGAGCTCCTTAG-3=  5=-GGTCAAGCCAACCAGAAAGA-3=  161 bp  A2B  5=-CAGTTGTTGGTGGCACTGTCTT-3=  5=-CTCACGCAGAGCTCCATCTTC-3==  200 bp  P2X4  5=-CCGTGGAGGATGACACACAC-3=  5=-GGCTCTGTCCAGGTTGCAGT-3=  302 bp  P2X7  5=-TAAAAGTCTTCGGGATCCGTTT-3=  5=-CTGGTTCACCATCCTAATGTGG-3=  334 bp  P2Y2  5=-TCTACTTTGTCACCACCAGCG-3=  5=-TTGATGGCGTTGAGGGTGTG-3=  349 bp  P2Y4  5=-TCGTGCCCAACCTGTTCTTT-3=  5=-TAAATGGTGCGGGTGATGTG-3=  304 bp  P2Y6  5=-GCTGCCTGGCTAGTGTGTGT-3=  5=-AAGTAGAAGAGGATGGGCTCCA-3=  482 bp  ANGPT1  5=-GCTGAACGGTCACACAGAGA-3=  5=-CTTTCCCCCTCAAAGAAAGC-3=  180 bp  ANGPT2  5=-TTATCACAGCACCAGCAAGC-3=  5=-TTCGCGAGAACAAATGTGAG-3=  223 bp  Tie1 5=-GAGAGTGACCCAGCTTTTGC-3= 5=-CTGCAATCTTGGAGGCTAGG-3= 184 bp Tie2 5=-TACACCTGCCTCATGCTCAG-3= 5=-TTCACAAGCCTTCTCACACG-3= 242 bp VEGFA 5=-AAGGAGGAGGGCAGAATCAT-3= 5=-ATCTGCATGGTGATGTTGGA-3= 226 bp VEGFR2 5=-AGCGATGGCCTCTTCTGTAA-3= 5=-ACACGACTCCATGTTGGTCA-3= 172 bp PDGFb 5=-CCCCACACTCCACTCTGATT-3= 5=-GCCCTGGCCTCTAGTCTTCT-3= 181 bp ␤-actin 5=-TCCCTGGAGAAGAGCTACGA-3= 5=-AGCACTGTGTTGGCGTACAG-3= 194 bp GAPDH 5=-TGCCAAATATGATGACATCAAGAA-3= 5=-GGAGTGGGTGTCGCTGTTG-3= 121 bp angiogenesis. Notably, another dinucleotide Up 4 U, with two pyrimidine moieties, has been recently shown to be a potent angiogenic factor in human vascular endothelial cells, inducing migration, proliferation, and tube formation, likely by activation of P2Y 2 R (24). Similarly to Up 4 A, most of the cell responses induced by Up 4 U showed a typical dose range effect with limited to no reaction beyond the optimal concentration (24) . Other dinucleotide polyphosphates, such as Ap 4 A with two purine moieties, have been reported to be angiogenic inert (29) . Since the pyrimidines UTP and UDP preferably activate P2Y 2 R, P2Y 4 R, and P2Y 6 R (33), these different observations for the dinucleotide polyphosphates group regarding angiogenic potential may be explained by the differences in binding properties of the purine and pyrimidine moieties. The fourphosphate groups do not vary between the dinucleotides and thus do not appear to be the decisive factor in compoundreceptor signaling in the angiogenic process. In accordance with this concept, it is likely that the purine moieties from Up 4 A do not have an effect on angiogenesis in HUVECs or HMVECs, even though Up 4 A, with both purine and pyrimidine moieties, is capable of activating both P1Rs and P2Rs (25, 44, 45). In line with the concept that Up 4 A mainly exerts proangiogenic actions via its pyrimidine moiety, tubule formation in the coculture setup was significantly attenuated by P2Y 6 R inhibition. Furthermore, our q-PCR data revealed that Up 4 A upregulated pyrimidine-favored P2YRs (P2Y 2 R, P2Y 4 R, and P2Y 6 R) but not P2XRs or P1Rs at mRNA levels. This Up 4 Ainduced expression response was in part blunted by P2Y 6 R inhibition, indicating a feed-forward loop in which Up 4 A activation of P2Y 6 R amplifies gene expression of P2Y 6 R. In addition, the observation that the potent and selective P2Y 6 R antagonist MRS2578 also significantly attenuated P2Y 2 R expression suggests a possible interaction between P2Y 6 R and P2Y 2 R (41). MRS2578 is well known to potently and selectively inhibit P2Y 6 R-mediated actions in several cell types (21, 26, 30, 32, 34, 43) , MRS2578 at 10 M potently inhibits P2Y 6 R but has been shown to have very minimal effect on P2Y 2 R in 1321N astrocytoma cells (30) . Future studies are needed to gain more insights into the interaction of PRs.
As shown in the data provided in Figs 4 A conditions, the effect of the blocker is partially reversed by the effect of Up 4 A, which leads to increased P2Y 6 R expression and receptor bioavailability, thereby counteracting the effect of the MRS2578 blocker. In the condition with only MRS2578 and no exogenous Up 4 A stimulation, the anti-angiogenic effects of MRS2578 would therefore also be more severe.
All together, these findings suggest that P2YRs, particularly P2Y 6 R, are involved in Up 4 A-mediated angiogenic influence in human endothelial cells. Although Up 4 A has been shown to activate not only P2YRs but also P1Rs and P2XRs, all of which appear to be involved in the regulation of vascular tone by Up 4 A (31, 44), the concept that only pyrimidine but not purine moieties affect function in HUVECs and HMVECs is further supported by recent studies performed at the cellular level: Up 4 A induces human vascular smooth muscle cell proliferation via activation of P2Y receptors (16) and is a strong inductor of migration in vascular smooth muscle cell obtained from rat thoracic aorta through activation of P2Y 2 receptors (42). Moreover, Up 4 A has been shown to influence phenotypic trans-differentiation of rat vascular smooth muscle cells to osteochondrogenic cells, likely via P2Y 2 and P2Y 6 receptors (37) . Further studies are required to validate if pyrimidine moieties and endothelial P2YR signaling are indeed a vital requirement for the angiogenic potential for the different compounds of the nucleotide polyphosphates group.
In the present study, Up 4 A also promoted mRNA expression of the proangiogenic genes ANGPT1 and VEGFA. Furthermore, Western blot analysis indicated that VEGFA protein levels were significantly increased in response to Up 4 A stimulation. In contrast, ANGPT1 protein levels were not significantly altered. This poor correlation between ANGPT1 protein and mRNA level could be the result of a shorter half-life of the ANGPT1 protein compared with VEGFA protein or could be associated with differences in posttranscriptional regulation between ANGPT1 and VEGFA protein levels (15) . Previous reports demonstrated that purinergic receptor-induced angiogenesis could be mediated by autocrine stimulation of vascular cells by proangiogenic factors (2, 14, 35) . Other studies have also indicated that Up 4 A can be biosynthesized by activation of VEGFR 2 (23) . An autocrine feed-forward loop exists, in which VEGFA signaling via VEGFR 2 promotes intracellular transport of VEGFR 2 to the plasma membrane, thus amplifying the bioavailability of this receptor tyrosine kinase on the endothelial cell surface (40) . This intrinsic pathway may further enhance Up 4 A synthesis and downstream vascular effects. New vascular growth is a complex, multiphasic process, during which both endothelial cells and mural cells (pericytes in the microvasculature and vascular smooth muscle cells in the macrovasculature) undergo activation, sprouting, and neovessel stabilization. VEGFA/VEGFR 2 signaling drives the typical initial response of vascular activation and is critical for neovascular growth and survival (28) . Up 4 A may facilitate its proangiogenic function via upregulation of mRNA and protein levels of VEGFA in endothelial cells.
Methodological considerations. Since Up 4 A mainly affected P2YR subtypes in our study, we used a pharmacological blocker of P2Y 6 R (MRS2578) to investigate the signaling pathway in the Up 4 A-mediated angiogenic process. The potential pitfall of using pharmacological blockers is that while selectivity, i.e., the capability of blocking a particular receptor compared with related receptors, is usually well-defined, specificity, i.e., the potential for discriminating between negative and positive interactions and the cross reactivity with other (unrelated) targets, is less well established (36) . However, MRS2578 has been reported to potently inhibit the response to 300 nM UDP in 1321N astrocytoma transfected with the human P2Y 6 R, with an IC50 value of 37 Ϯ 16 nM (30) . At the same time, MRS2578 at 10 M did not affect the UTP (100 nM)-induced responses of cells expressing human P2Y 2 R or The effects on tubule formation were mainly observed for 5 M Up 4 A, whereas mRNA expression of PRs and angiogenic factors responded mainly to 10 M Up 4 A. Similar to our HUVEC data, our additional experiments performed in HMVECs and HAECs showed a comparable pattern of tubule formation predominantly responding to 5 M Up 4 A, whereas mRNA of PRs and angiogenic factors responded mainly to 10 M Up 4 A (Figs. 1 and 4) . Thus, the difference in responsive dose between coculture and mRNA expression, was not endothelial cell type specific. This difference in effective dose may be attributed to the difference in our setup between normal (2-dimensional) endothelial cell culture (to yield samples for q-PCR) and our 3D collagen matrix endothelial-pericyte coculture setup. For the 3D coculture, HUVECs/HMVECs and pericytes were before the experiment both lentivirally transfected with GFP and dsRED expression cassettes to obtain stable HUVEC/HUMVEC-GFP and pericyte-dsRED cells. These HUVEC/HMVEC-GFP and pericyte-dsRED cells have undergone several passages of selection to obtain a 99% pure marker expressing population. In contrast, for q-PCR analysis, we used HUVECs and HAECs that were not treated with lentivirus and were not selected for several passages on GFP or dsRED marker expression. This difference in treatment of the cells before the experiments could have affected their sensitivity and actual response to Up 4 A stimulation (e.g., the GFP cells could have adapted to express higher levels of receptors, or have down-regulated inhibitory pathways that intervene with Up 4 A receptor signaling). Furthermore, the coculture assay was conducted in a 3D matrix environment, whereas for q-PCR, the cells were cultured under normal conditions without complex extracellular matrix support. This may also have affected the responsiveness of the vascular cells. For example, interaction of endothelial cells with complex extracellular matrix components such as collagen type 1 fibers via integrin interaction is known to aid activation of endothelial angiogenic sprouting (11) . In addition, the phenotypical changes in the 3D coculture assay were the result of transcriptional changes in multiple genes, which, combined together, resulted in the phenotype (tubule formation). Therefore, even if transcriptional changes were slightly but nonsignificantly increased in response to 5 M Up 4 A stimulation, combined, this could have still contributed to the acquired phenotype.
Another limitation of our study is that different batches of HUVECs (GFP) and collagen were used for the experiments in Figs. 1 and 3 , which may have resulted in the differences observed in tubule formation response to 1 M Up 4 A. However, Up 4 A at 5 M affected the tubule formation in a very similar pattern between these two experiments, indicating that Up 4 A at 5 M may be the optimal concentration for a more stable tubule formation response that surpasses these batch effects. Thus, although the optimal dose and the net amount of increase in angiogenesis varied, these experiments clearly showed that Up 4 A could consistently induce a solid proangiogenic response. These findings were further verified by our HMVECs and pericytes coculture assays. We therefore conclude that Up 4 A has a strong angiogenic potential, but the optimal dose may vary between endothelial cell populations of different donors. For future clinical use of Up 4 A as a therapeutic agent in angiogenic stimulation, establishing the optimal dose range for specific subtypes of patients will be a crucial requirement.
Conclusions. We have identified, to our knowledge for the first time, the dinucleotide polyphosphate Up 4 A as a novel angiogenic substance, which promotes sprouting and tubule formation in human vascular cells in vitro. This Up 4 A proangiogenic function is mediated via P2Y 6 R signaling and is associated with upregulation of P2YRs and the proangiogenic factors.
